文献速递免疫规划传染病防控与疫情报告

接受美沙酮维持治疗患者接种高剂量乙型肝炎疫苗的免疫原性与安全性:一项随机双盲平行对照试验

Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial.
PubMed 文献 · Vaccine · 2017-03-23

该随机双盲平行对照试验将196例美沙酮维持治疗患者按1:1随机分配,分别在第0、1、6月接种20μg或60μg重组乙型肝炎疫苗。60μg组第7月抗-HBs血清转换率87.3%、高水平应答率56.3%、几何平均浓度742.9mIU/mL,数值上高于20μg组但未达统计学差异。HIV感染与合并药物滥用与稳健免疫应答呈负相关。

要点

  • 60μg组第7月抗-HBs血清转换率87.3%、高水平应答率56.3%、GMC 742.9mIU/mL,数值上高于20μg组但无统计学差异。
  • HIV感染与合并药物滥用与稳健免疫应答呈负相关。
  • 接种至少一剂者中7.7%报告7天内征集性不良反应,2.6%报告28天内非征集性不良反应,无严重不良事件。

核心结论

  • 第0、1、6月三剂60μg重组乙型肝炎疫苗方案在美沙酮维持治疗患者中产生的免疫原性与20μg疫苗相似。

研究设计与样本

  • 随机、双盲、平行对照试验,纳入血清HBsAg与抗-HBs均阴性的美沙酮维持治疗患者,按1:1随机分配至20μg或60μg重组乙型肝炎疫苗组,于第0、1、6月肌肉注射三剂,第7月和第12月检测血清HBsAg和抗-HBs以评估免疫原性。
  • 共196例美沙酮维持治疗患者被随机分配,195例至少接受一剂注射(20μg疫苗组98例,60μg疫苗组97例)。

主要发现

  • 60μg疫苗组第7月抗-HBs血清转换率为87.3%,高水平应答率为56.3%,GMC为742.9mIU/mL;这些结果数值上高于20μg组,但未发现统计学差异。
  • HIV感染与合并药物滥用与稳健免疫应答呈负相关。
  • 接受至少一剂疫苗的美沙酮维持治疗患者中,7.7%在接种后7天内报告征集性不良反应,2.6%在接种后28天内报告非征集性不良反应。
  • 随访期间无美沙酮维持治疗患者报告严重不良事件或HBsAg转阳。

关键数值与推荐

  • 60μg疫苗组第7月抗-HBs血清转换率87.3%、高水平应答率56.3%、GMC 742.9mIU/mL;20μg组对应数值原文未报告。
  • 接受至少一剂疫苗者中,7.7%报告7天内征集性不良反应,2.6%报告28天内非征集性不良反应。
  • 随访期间无严重不良事件报告,无患者HBsAg转阳。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: To explore whether the immunization with high-dose (60μg) hepatitis B vaccines in patients receiving methadone maintenance treatment (MMT) could yield a superior protection against hepatitis B infection than did the standard dose (20μg). METHODS: We conducted a randomized, double-blinded, parallel-controlled trial in MMT patients. Patients with serologically negative hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) were randomized in a ratio of 1:1 to receive three intramuscular injections of 20μg or 60μg recombinant hepatitis B vaccine at months 0, 1, and 6. Serum HBsAg and anti-HBs were measured at months 7 and 12 post-vaccination to assess the immunogenicity. RESULTS: A total of 196 MMT patients were randomized and 195 received at least one injection (98 and 97 in 20 and 60μg vaccine groups, respectively). The 60μg vaccine group showed a seroconversion of anti-HBs of 87.3%, high-level response rate of 56.3%, and GMC of 742.9mIU/mL at month 7. While these results were numerically higher than the 20μg group, a statistical difference was not found. HIV infection and concomitant drug abuse were negatively associated with the robust immune responses. 7.7% of MMT patients receiving at least one dose of vaccine reported solicited adverse reactions within 7days after vaccination, 2.6% reported unsolicited adverse reactions within 28days after vaccination. None of the MMT patients reported serious adverse events or became HBsAg positive during the follow-up. CONCLUSIONS: The three-dose regimen of 60μg recombinant hepatitis B vaccine at months 0, 1, and 6 can yield a similar immunogenicity among MMT patients as compared to the 20μg vaccine. ClinicalTrials.gov identifier: NCT02991599.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shi J, Feng Y, Gao L, et al. Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial. Vaccine. 2017. PMID: 28343774. doi:10.1016/j.vaccine.2017.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。